Are Hemodynamics Surrogate End Points in Pulmonary Arterial Hypertension?
Authors:
- Corey E. VentetuoloCVCorey E. Ventetuolo
- Nicole B. GablerNGNicole B. Gabler
- Jason S. FritzJFJason S. Fritz
- K. Akaya SmithKSK. Akaya Smith
- Harold I. PalevskyHPHarold I. Palevsky
- James R. KlingerJKJames R. Klinger
- Scott D. HalpernSHScott D. Halpern
- Steven M. KawutSKSteven M. Kawut
- 26 August 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 130 (9) , 768-775
Abstract
Background—: Although frequently assessed in trials and clinical practice, hemodynamic response to therapy has never been validated as a surrogate end point for clinical events in pulmonary arterial hypertension (PAH). Methods and Results—: We performed a patient-level pooled analysis of 4 randomized, placebo-controlled trials to determine whether treatment-induced changes in hemodynamic values at 12 weeks accounted for the relationship between treatment assignment and the probability of early clinical events (death, lung transplantation, atrial septostomy, PAH hospitalization, withdrawal for clinical worsening, or escalation in PAH therapy). We included 1119 subjects with PAH. The median (interquartile range) age was 48 years (37–59 years), and 23% were men. A total of 656 patients (59%) received active therapy (101 [15%] iloprost, 118 [18%] sitaxsentan, 204 [31%] sildenafil, and 233 [36%] subcutaneous treprostinil). Active treatment significantly lowered right atrial pressure, mean pulmonary artery pressure, and pulmonary vascular resistance and increased cardiac output and index ( P P P <0.001), changes in hemodynamics accounted for only 1.2% to 13.9% of the overall treatment effect. Conclusions—: Treatment-induced changes in hemodynamics at 12 weeks only partially explain the impact of therapy on the probability of early clinical events in PAH. These findings suggest that resting hemodynamics are not valid surrogate end points for short-term events in PAH clinical trials.Keywords
This publication has 51 references indexed in Scilit:
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Lung 18F-Fluorodeoxyglucose Positron Emission Tomography for Diagnosis and Monitoring of Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertensionPulmonary Pharmacology & Therapeutics, 2012
- Evaluating the Proportion of Treatment Effect Explained by a Continuous Surrogate Marker in Logistic or Probit Regression ModelsStatistics in Biopharmaceutical Research, 2010
- Tadalafil Therapy for Pulmonary Arterial HypertensionCirculation, 2009
- Use of Multiple Imputation in the Epidemiologic LiteratureAmerican Journal of Epidemiology, 2008
- Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertensionAmerican Heart Journal, 2008
- Favorable Effects of Inhaled Treprostinil in Severe Pulmonary HypertensionJACC, 2006
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992